中国原创新药泽立美研究成果亮相国际皮肤病学大会

Core Insights - The 14th International Congress of Dermatology (ICD) was held in Rome, Italy, focusing on advancements in dermatology, attracting over 5,000 dermatology experts globally [1] - The Chinese team presented the innovative drug Zeli Mei (Benvimod) for treating atopic dermatitis (AD), which has garnered significant attention for offering new hope to AD patients worldwide [1] Group 1: Drug Mechanism and Benefits - Zeli Mei is the world's first non-steroidal topical aryl hydrocarbon receptor (AhR) modulator, overcoming the limitations of traditional steroid treatments that can damage skin cells and weaken the skin barrier [1] - The drug has a fourfold therapeutic mechanism: inhibiting inflammatory response, repairing skin barrier, antioxidant stress response, and balancing skin microbiome, showcasing significant advantages in treating AD [1] Group 2: Clinical Efficacy - Clinical research demonstrated Zeli Mei's outstanding efficacy in both children and adults with AD, achieving an EASI-75 response rate of 54.4% after 8 weeks, with a remarkable 69.2% in children aged 2-17, and 83.9% in the 7-11 age group [2] - It was noted that itchiness, a critical symptom for AD patients, showed significant improvement as early as the second day of treatment, enhancing the quality of life for patients, especially children [2] Group 3: Long-term Management and Approvals - Zeli Mei exhibited excellent long-term management results, with a 70% rate of no disease relapse after 52 weeks of treatment and follow-up, indicating durable and stable treatment effects [2] - The drug has been approved for use in AD patients aged 2 and above in both China and the United States, with China granting approval a month earlier, highlighting the efficiency of China's drug review process [2]